J&J claims first approval for PARP combo Akeega

J&J claims first approval for PARP combo Akeega

Source: 
Pharmaphorum
snippet: 

Johnson & Johnson has picked up its first regulatory approval worldwide for Akeega, a fixed-dose combination of a PARP inhibitor and anti-androgen therapy, as a treatment for patients with metastatic castration-resistant prostate cancer (mCRPC),